Tusamitamab Ravtansine in Patients with Advanced Solid Tumors: Phase I Study of Safety, Pharmacokinetics, and Antitumor Activity Using Alternative Dosing Regimens

by on 29 d'abril de 2024 with No hi ha comentaris
  • Tabernero, J., Bedard, P. L., Bang, Y. J., Vieito, M., Ryu, M. H., Fagniez, N., . . . Gazzah, A. (2023). Tusamitamab Ravtansine in Patients with Advanced Solid Tumors: Phase I Study of Safety, Pharmacokinetics, and Antitumor Activity Using Alternative Dosing Regimens. Cancer Research Communications, 3(8), 1662-1671. https://doi.org/10.1158/2767-9764.crc-23-0284

Deixa un comentari

L'adreça electrònica no es publicarà. Els camps necessaris estan marcats amb *